Targeting a specific receptor to improve treatments for Alzheimer's disease
Chemical Tools to Target TREM2 in Alzheimer's Disease
This study is exploring a special receptor called TREM2 to help scientists find new ways to treat Alzheimer's disease, which could lead to better options for patients looking to slow down or stop the progression of their condition.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wichita State University NIH-funded |
| Lab location | 1 site (Wichita, United States) |
| Project ID | NIH-10580318 on NIH RePORTER |
What this research studies
This research focuses on the TREM2 receptor, which has been identified as a promising target for developing new therapies for Alzheimer's disease. The project aims to create chemical tools that will help researchers understand how TREM2 functions and its role in the progression of Alzheimer's. By developing methods to study TREM2's structure and interactions, the research seeks to uncover new therapeutic strategies that could lead to effective treatments. Patients may benefit from advancements in understanding and targeting this receptor to slow or halt disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk due to genetic factors associated with TREM2.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that improve outcomes for patients with Alzheimer's disease.
How similar studies have performed: Other research has shown promise in targeting similar receptors for Alzheimer's treatment, indicating a potential for success in this approach.
Where this research is happening
Wichita, United States
- Wichita State University — Wichita, United States (Active)
Researchers
- Principal investigator: Wu, Haifan — Wichita State University
- Study coordinator: Wu, Haifan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.